Verition Fund Management
AMRX icon

Verition Fund Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Verition Fund Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,247
Closed -$784K – 2267
2025
Q4 		$784K Sell
62,247
-62,568
-50% -$716K ﹤0.01% 2337
2025
Q3 		$1.25M Buy
124,815
+89,448
+253% +$803K 0.01% 2351
2025
Q2 		$286K Sell
35,367
-92,227
-72% -$695K ﹤0.01% 3226
2025
Q1 		$1.07M Sell
127,594
-12,144
-9% -$101K 0.01% 2078
2024
Q4 		$1.11M Buy
139,738
+93,394
+202% +$784K ﹤0.01% 1978
2024
Q3 		$386K Sell
46,344
-5,673
-11% -$44.4K ﹤0.01% 2482
2024
Q2 		$330K Buy
+52,017
New +$330K ﹤0.01% 2286
2023
Q4 		– Sell
-17,400
Closed -$73.4K – 2312
2023
Q3 		$73.4K Buy
+17,400
New +$64.9K ﹤0.01% 2144
2023
Q2 		– Sell
-23,154
Closed -$32.2K – 2190
2023
Q1 		$32.2K Buy
23,154
+11,554
+100% +$23K ﹤0.01% 1984
2022
Q4 		$23.1K Buy
+11,600
New +$26K ﹤0.01% 1926

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Verition Fund Management's AMRX Position: Q1 2026 in Review

Verition Fund Management sold out of Amneal Pharmaceuticals (AMRX) in Q1 2026, closing a stake of 62,247 shares — an estimated $784K sold.

Verition Fund Management first reported a position in AMRX in Q4 2022 and held it in 10 quarters. The position peaked at $1.25M in Q3 2025. 317 funds tracked by Wall St. Rank hold AMRX as of Q1 2026.

  • Verition Fund Management reported no remaining Amneal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 62,247 Amneal Pharmaceuticals shares in Q1 2026, an estimated $784K.
  • Verition Fund Management first reported a position in Amneal Pharmaceuticals in Q4 2022 and held it in 10 quarters.
  • Verition Fund Management's Amneal Pharmaceuticals position peaked at $1.25M in Q3 2025.
  • 317 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.